Iambic Therapeutics completes IPO, raising $150 million and pricing shares at $16
AI drug discovery company Iambic Therapeutics successfully completed its initial public offering (IPO). The company priced its shares at $16 each, raising a total of $150 million. Investing.com reported the share price and Nasdaq listing, while Bloomberg, Dealroom, and BioPharma Dive confirmed the $150 million raised. Bloomberg also noted Iambic's backing by Nvidia. The funds are intended to support Iambic's pipeline of AI-discovered drugs.
4 articles from 4 outlets covered this story. The underlying claim is sourced from a press release.
What do all outlets agree on?
4 outlets covered “Iambic Therapeutics completes IPO, raising $150 million and pricing shares at $16”. All of them report the following:
- Iambic Therapeutics completed an IPO
- The company is an AI drug discovery specialist
- The IPO raised $150 million
Which outlets covered this?
All 4 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.